Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway

Min Zhang, Yasunobe Abe, Takamitsu Matsushima, Junji Nishimura, Hajime Nawata, Koichiro Muta

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

NS-398, a selective inhibitor of cyclooxygenase 2 (COX-2), has been reported to inhibit growth and induce apoptosis in several cancer cell lines that overexpress COX-2. However it has not been extensively studied in multiple myeloma (MM). Here, we studied the effects of COX-2 inhibitors on MM cell lines and primary myeloma patient cells. We investigated the effects of NS-398 on proliferation and apoptosis in three myeloma cell lines (PCM6, U266 and RPMI8226) and isolated CD138-positive cells from MM patients. Furthermore, the combined effects of NS-398 plus dexamethasone (Dex) or thalidomide (Thal) were investigated. All myeloma cell lines express COX-2. NS-398 inhibited growth and induced apoptosis in PCM6, RPMI8226 and CD138-positive MM cells in a time- and dose-dependent manner. At low concentrations (10 μM), NS-398 primarily induced growth arrest without affecting cell viability, but at higher concentrations (over 25 μM), apoptosis was induced. During the process of apoptosis, the number of Fas-positive cells increased. Downstream signals of Fas, such as caspase 8, 3 and 9, were also activated. On the other hand, protein levels of the Bcl-2 family did not change, although mitochondrial transmembrane potential (Δψm) was decreased. Combined incubation with Dex or Thal enhanced NS-398-induced growth inhibition and apoptosis in RPM18226 cells. The combined effect of Dex was more potent than that of Thal. Our findings suggests that COX-2 plays an important role in regulation of apoptosis in myeloma cells, and COX-2 inhibitors might serve as an effective tool for future chemoprevention and/or treatment of myeloma.

Original languageEnglish
Pages (from-to)425-433
Number of pages9
JournalLeukemia and Lymphoma
Volume46
Issue number3
DOIs
Publication statusPublished - Mar 1 2005

Fingerprint

Cyclooxygenase 2 Inhibitors
Apoptosis
Multiple Myeloma
Thalidomide
Cyclooxygenase 2
Dexamethasone
Cell Line
Growth
Caspase 9
Caspase 8
Chemoprevention
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
Caspase 3
Membrane Potentials
Cell Survival
Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. / Zhang, Min; Abe, Yasunobe; Matsushima, Takamitsu; Nishimura, Junji; Nawata, Hajime; Muta, Koichiro.

In: Leukemia and Lymphoma, Vol. 46, No. 3, 01.03.2005, p. 425-433.

Research output: Contribution to journalArticle

Zhang, Min ; Abe, Yasunobe ; Matsushima, Takamitsu ; Nishimura, Junji ; Nawata, Hajime ; Muta, Koichiro. / Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. In: Leukemia and Lymphoma. 2005 ; Vol. 46, No. 3. pp. 425-433.
@article{d57511eaae9c4f41b8b8b47ed78fffea,
title = "Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway",
abstract = "NS-398, a selective inhibitor of cyclooxygenase 2 (COX-2), has been reported to inhibit growth and induce apoptosis in several cancer cell lines that overexpress COX-2. However it has not been extensively studied in multiple myeloma (MM). Here, we studied the effects of COX-2 inhibitors on MM cell lines and primary myeloma patient cells. We investigated the effects of NS-398 on proliferation and apoptosis in three myeloma cell lines (PCM6, U266 and RPMI8226) and isolated CD138-positive cells from MM patients. Furthermore, the combined effects of NS-398 plus dexamethasone (Dex) or thalidomide (Thal) were investigated. All myeloma cell lines express COX-2. NS-398 inhibited growth and induced apoptosis in PCM6, RPMI8226 and CD138-positive MM cells in a time- and dose-dependent manner. At low concentrations (10 μM), NS-398 primarily induced growth arrest without affecting cell viability, but at higher concentrations (over 25 μM), apoptosis was induced. During the process of apoptosis, the number of Fas-positive cells increased. Downstream signals of Fas, such as caspase 8, 3 and 9, were also activated. On the other hand, protein levels of the Bcl-2 family did not change, although mitochondrial transmembrane potential (Δψm) was decreased. Combined incubation with Dex or Thal enhanced NS-398-induced growth inhibition and apoptosis in RPM18226 cells. The combined effect of Dex was more potent than that of Thal. Our findings suggests that COX-2 plays an important role in regulation of apoptosis in myeloma cells, and COX-2 inhibitors might serve as an effective tool for future chemoprevention and/or treatment of myeloma.",
author = "Min Zhang and Yasunobe Abe and Takamitsu Matsushima and Junji Nishimura and Hajime Nawata and Koichiro Muta",
year = "2005",
month = "3",
day = "1",
doi = "10.1080/10428190400015691",
language = "English",
volume = "46",
pages = "425--433",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway

AU - Zhang, Min

AU - Abe, Yasunobe

AU - Matsushima, Takamitsu

AU - Nishimura, Junji

AU - Nawata, Hajime

AU - Muta, Koichiro

PY - 2005/3/1

Y1 - 2005/3/1

N2 - NS-398, a selective inhibitor of cyclooxygenase 2 (COX-2), has been reported to inhibit growth and induce apoptosis in several cancer cell lines that overexpress COX-2. However it has not been extensively studied in multiple myeloma (MM). Here, we studied the effects of COX-2 inhibitors on MM cell lines and primary myeloma patient cells. We investigated the effects of NS-398 on proliferation and apoptosis in three myeloma cell lines (PCM6, U266 and RPMI8226) and isolated CD138-positive cells from MM patients. Furthermore, the combined effects of NS-398 plus dexamethasone (Dex) or thalidomide (Thal) were investigated. All myeloma cell lines express COX-2. NS-398 inhibited growth and induced apoptosis in PCM6, RPMI8226 and CD138-positive MM cells in a time- and dose-dependent manner. At low concentrations (10 μM), NS-398 primarily induced growth arrest without affecting cell viability, but at higher concentrations (over 25 μM), apoptosis was induced. During the process of apoptosis, the number of Fas-positive cells increased. Downstream signals of Fas, such as caspase 8, 3 and 9, were also activated. On the other hand, protein levels of the Bcl-2 family did not change, although mitochondrial transmembrane potential (Δψm) was decreased. Combined incubation with Dex or Thal enhanced NS-398-induced growth inhibition and apoptosis in RPM18226 cells. The combined effect of Dex was more potent than that of Thal. Our findings suggests that COX-2 plays an important role in regulation of apoptosis in myeloma cells, and COX-2 inhibitors might serve as an effective tool for future chemoprevention and/or treatment of myeloma.

AB - NS-398, a selective inhibitor of cyclooxygenase 2 (COX-2), has been reported to inhibit growth and induce apoptosis in several cancer cell lines that overexpress COX-2. However it has not been extensively studied in multiple myeloma (MM). Here, we studied the effects of COX-2 inhibitors on MM cell lines and primary myeloma patient cells. We investigated the effects of NS-398 on proliferation and apoptosis in three myeloma cell lines (PCM6, U266 and RPMI8226) and isolated CD138-positive cells from MM patients. Furthermore, the combined effects of NS-398 plus dexamethasone (Dex) or thalidomide (Thal) were investigated. All myeloma cell lines express COX-2. NS-398 inhibited growth and induced apoptosis in PCM6, RPMI8226 and CD138-positive MM cells in a time- and dose-dependent manner. At low concentrations (10 μM), NS-398 primarily induced growth arrest without affecting cell viability, but at higher concentrations (over 25 μM), apoptosis was induced. During the process of apoptosis, the number of Fas-positive cells increased. Downstream signals of Fas, such as caspase 8, 3 and 9, were also activated. On the other hand, protein levels of the Bcl-2 family did not change, although mitochondrial transmembrane potential (Δψm) was decreased. Combined incubation with Dex or Thal enhanced NS-398-induced growth inhibition and apoptosis in RPM18226 cells. The combined effect of Dex was more potent than that of Thal. Our findings suggests that COX-2 plays an important role in regulation of apoptosis in myeloma cells, and COX-2 inhibitors might serve as an effective tool for future chemoprevention and/or treatment of myeloma.

UR - http://www.scopus.com/inward/record.url?scp=13544262684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544262684&partnerID=8YFLogxK

U2 - 10.1080/10428190400015691

DO - 10.1080/10428190400015691

M3 - Article

VL - 46

SP - 425

EP - 433

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -